Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
作者： Shaji K Kumar , Jesus G Berdeja , Ruben Niesvizky , Sagar Lonial , Jacob P Laubach
DOI: 10.1016/S1470-2045(14)71125-8
关键词:
摘要: … dose of ixazomib in combination with lenalidomide and low-dose dexamethasone to be 2·97 mg/m 2 . The recommended phase 2 dose of ixazomib was 2·23 mg/m 2 given on days 1, 8, …
elsevier.com
lancet.com 参考文章(29)
Neeraj Gupta, Yuan Zhao, Ai-Min Hui, Dixie-Lee Esseltine, Karthik Venkatakrishnan, Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis British Journal of Clinical Pharmacology. ,vol. 79, pp. 789- 800 ,(2015) , 10.1111/BCP.12542
Paul G. Richardson, Edie Weller, Sagar Lonial, Andrzej J. Jakubowiak, Sundar Jagannath, Noopur S. Raje, David E. Avigan, Wanling Xie, Irene M. Ghobrial, Robert L. Schlossman, Amitabha Mazumder, Nikhil C. Munshi, David H. Vesole, Robin Joyce, Jonathan L. Kaufman, Deborah Doss, Diane L. Warren, Laura E. Lunde, Sarah Kaster, Carol DeLaney, Teru Hideshima, Constantine S. Mitsiades, Robert Knight, Dixie-Lee Esseltine, Kenneth C. Anderson, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. ,vol. 116, pp. 679- 686 ,(2010) , 10.1182/BLOOD-2010-02-268862
Shaji K. Kumar, William I. Bensinger, Todd M. Zimmerman, Craig B. Reeder, James R. Berenson, Deborah Berg, Ai-Min Hui, Neeraj Gupta, Alessandra Di Bacco, Jiang Yu, Yaping Shou, Ruben Niesvizky, Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma Blood. ,vol. 124, pp. 1047- 1055 ,(2014) , 10.1182/BLOOD-2014-01-548941
Andrzej J. Jakubowiak, Kent A. Griffith, Donna E. Reece, Craig C. Hofmeister, Sagar Lonial, Todd M. Zimmerman, Erica L. Campagnaro, Robert L. Schlossman, Jacob P. Laubach, Noopur S. Raje, Tara Anderson, Melissa A. Mietzel, Colleen K. Harvey, Sandra M. Wear, Jennifer C. Barrickman, Craig L. Tendler, Dixie-Lee Esseltine, Susan L. Kelley, Mark S. Kaminski, Kenneth C. Anderson, Paul G. Richardson, Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial Blood. ,vol. 118, pp. 535- 543 ,(2011) , 10.1182/BLOOD-2011-02-334755
Shaji Kumar, Ian Flinn, Paul G. Richardson, Parameswaran Hari, Natalie Callander, Stephen J. Noga, A. Keith Stewart, Francesco Turturro, Robert Rifkin, Jeffrey Wolf, Jose Estevam, George Mulligan, Hongliang Shi, Iain J. Webb, S. Vincent Rajkumar, Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma Blood. ,vol. 119, pp. 4375- 4382 ,(2012) , 10.1182/BLOOD-2011-11-395749
S K Kumar, A Dispenzieri, M Q Lacy, M A Gertz, F K Buadi, S Pandey, P Kapoor, D Dingli, S R Hayman, N Leung, J Lust, A McCurdy, S J Russell, S R Zeldenrust, R A Kyle, S V Rajkumar, Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Leukemia. ,vol. 28, pp. 1122- 1128 ,(2014) , 10.1038/LEU.2013.313
Paul G. Richardson, Rachid Baz, Michael Wang, Andrzej J. Jakubowiak, Jacob P. Laubach, R. Donald Harvey, Moshe Talpaz, Deborah Berg, Guohui Liu, Jiang Yu, Neeraj Gupta, Alessandra Di Bacco, Ai-Min Hui, Sagar Lonial, Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. ,vol. 124, pp. 1038- 1046 ,(2014) , 10.1182/BLOOD-2014-01-548826
Shaji K. Kumar, Joseph R. Mikhael, Francis K. Buadi, David Dingli, Angela Dispenzieri, Rafael Fonseca, Morie A. Gertz, Philip R. Greipp, Suzanne R. Hayman, Robert A. Kyle, Martha Q. Lacy, John A. Lust, Craig B. Reeder, Vivek Roy, Stephen J. Russell, Kristen E. Detweiler Short, A. Keith Stewart, Thomas E. Witzig, Steven R. Zeldenrust, Robert J. Dalton, S. Vincent Rajkumar, P. Leif Bergsagel, Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines Mayo Clinic Proceedings. ,vol. 84, pp. 1095- 1110 ,(2009) , 10.4065/MCP.2009.0603
J S Miguel, J Bladé, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G Gahrton, M Beksac, J Crowley, A Belch, M Boccadaro, I Turesson, D Joshua, D Vesole, R Kyle, R Alexanian, G Tricot, M Attal, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi, G Morgan, S V Rajkumar, B G M Durie, , J-L Harousseau, International uniform response criteria for multiple myeloma Leukemia. ,vol. 20, pp. 1467- 1473 ,(2006) , 10.1038/SJ.LEU.2404284
Michele Cavo, Paola Tacchetti, Francesca Patriarca, Maria Teresa Petrucci, Lucia Pantani, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Elena Zamagni, Antonio Palumbo, Massimo Offidani, Paolo Corradini, Franco Narni, Antonio Spadano, Norbert Pescosta, Giorgio Lambertenghi Deliliers, Antonio Ledda, Claudia Cellini, Tommaso Caravita, Patrizia Tosi, Michele Baccarani, None, Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study The Lancet. ,vol. 376, pp. 2075- 2085 ,(2010) , 10.1016/S0140-6736(10)61424-9